ofranergene
vbl therapeutics
['vb-111', 'ofranergene', 'paclitaxel', 'gyn', 'ovarian', 'oval study']
rebecca arend: randomized controlled phase iii trial of weekly paclitaxel ofranergene obadenovec (vb-111) for platinum-resistant ovarian cancer (oval study/gog 3018). #asco23 #gyncsm 
18-year Ovarian Cancer Survivor/Research Advocate. 2 recurrences, now 15 years NED. Loves laughter theater puzzles F1 & PoGO. Evidence based medicine=HOPE